Home News Prospects bullish for positive Ad Com vote for Spark’s gene therapy Luxturna...

Prospects bullish for positive Ad Com vote for Spark’s gene therapy Luxturna – Spark Therapeutics (NASDAQ:ONCE)

11
0
SHARE


The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee will vote in a short while on Spark Therapeutics’ (ONCE) marketing application for gene therapy LUXTURNA (voretigene neparvovec) for the treatment of RPE65 mutation-associated retinal dystrophy.

The patient testimonials were especially moving. It looks good for a thumbs up.

Trading, suspended since before 7:00 am ET this morning, should resume after the vote.



Source link

LEAVE A REPLY